De-risking immunotherapy: Report of a consensus workshop of the cancer immunotherapy consortium of the cancer research institute

Ira Mellman, Vanessa M. Hubbard-Lucey, Matthew J. Tontonoz, Michael D. Kalos, Daniel S. Chen, James P. Allison, Charles G. Drake, Hy Levitsky, Nils Lonberg, Sjoerd H. Van Der Burg, Douglas T. Fearon, E. John Wherry, Israel Lowy, Robert Hvonderheide, Patrick Hwu

Research output: Contribution to journalArticlepeer-review

Abstract

With the recent FDA approvals of pembrolizumab and nivolumab, and a host of additional immunomodulatory agents entering clinical development each year, the field of cancer immunotherapy is changing rapidly. Strategies that can assist researchers in choosing the most promising drugs and drug combinations to move forward through clinical development are badly needed in order to reduce the likelihood of late-stage clinical trial failures. On October 5, 2014, the Cancer Immunotherapy Consortium of the Cancer Research Institute, a collaborative think tank composed of stakeholders from academia, industry, regulatory agencies, and patient interest groups, met to discuss strategies for de-risking immunotherapy development, with a focus on integrating preclinical and clinical studies, and conducting smarter early-phase trials, particularly for combination therapies. Several recommendations were made, including making better use of clinical data to inform preclinical research, obtaining adequate tissues for biomarker studies, and choosing appropriate clinical trial endpoints to identify promising drug candidates and combinations in nonrandomized early-phase trials.

Original languageEnglish (US)
Pages (from-to)279-288
Number of pages10
JournalCancer immunology research
Volume4
Issue number4
DOIs
StatePublished - 2016

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Fingerprint

Dive into the research topics of 'De-risking immunotherapy: Report of a consensus workshop of the cancer immunotherapy consortium of the cancer research institute'. Together they form a unique fingerprint.

Cite this